YU58398A - Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv - Google Patents
Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hivInfo
- Publication number
- YU58398A YU58398A YU58398A YU58398A YU58398A YU 58398 A YU58398 A YU 58398A YU 58398 A YU58398 A YU 58398A YU 58398 A YU58398 A YU 58398A YU 58398 A YU58398 A YU 58398A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- hiv
- combinations
- amino
- ftc
- zidovudine
- Prior art date
Links
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title abstract 3
- 229960002555 zidovudine Drugs 0.000 title abstract 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 230000036436 anti-hiv Effects 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- -1 tetrahydro-3-furanyl ester Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2054396P | 1996-06-25 | 1996-06-25 | |
| US2102796P | 1996-07-02 | 1996-07-02 | |
| GBGB9614022.3A GB9614022D0 (en) | 1996-07-04 | 1996-07-04 | Antiviral therapeutic combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU58398A true YU58398A (en) | 1999-11-22 |
Family
ID=27268358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU58398A YU58398A (en) | 1996-06-25 | 1998-12-16 | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6544961B1 (sr) |
| EP (1) | EP0938321B1 (sr) |
| JP (1) | JP2000515852A (sr) |
| KR (1) | KR20000022226A (sr) |
| CN (1) | CN1228026A (sr) |
| AP (1) | AP9801419A0 (sr) |
| AT (1) | ATE257708T1 (sr) |
| AU (1) | AU727983B2 (sr) |
| BR (1) | BR9709939A (sr) |
| CA (1) | CA2258956A1 (sr) |
| CO (1) | CO4900074A1 (sr) |
| CZ (1) | CZ429498A3 (sr) |
| DE (1) | DE69727240T2 (sr) |
| EA (1) | EA001517B1 (sr) |
| ES (1) | ES2213217T3 (sr) |
| HU (1) | HUP9903249A3 (sr) |
| ID (1) | ID19490A (sr) |
| IL (1) | IL127351A0 (sr) |
| IS (1) | IS4915A (sr) |
| NO (1) | NO986034L (sr) |
| NZ (1) | NZ333099A (sr) |
| PL (1) | PL330747A1 (sr) |
| TR (1) | TR199802704T2 (sr) |
| TW (1) | TW469132B (sr) |
| WO (1) | WO1997049411A1 (sr) |
| YU (1) | YU58398A (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| AU4219799A (en) * | 1998-05-29 | 1999-12-13 | University Of Florida | Combination therapy for treatment of fiv infection |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| NZ554779A (en) * | 2005-02-01 | 2011-02-25 | Troikaa Pharmaceuticals Ltd | Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts |
| ES2279707B1 (es) * | 2005-11-10 | 2008-06-01 | Combino Pharm, S.L. | Formulaciones orales que comprenden 3'-azidonucleosidos. |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| US20110052580A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| MX367937B (es) * | 2010-01-27 | 2019-09-12 | Viiv Healthcare Co | Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
| GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
| SK279262B6 (sk) | 1991-05-16 | 1998-08-05 | Glaxo Group Limited | Protivírusová zmes, farmaceutický prostriedok s je |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9307013D0 (en) * | 1993-04-02 | 1993-05-26 | Wellcome Found | Therapeutic combinations |
| DK0656887T3 (da) | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| GB9503850D0 (en) | 1995-02-25 | 1995-04-19 | Glaxo Group Ltd | Medicaments |
| US5869461A (en) | 1995-03-16 | 1999-02-09 | Yale University | Reducing toxicity of L-nucleosides with D-nucleosides |
| MY115461A (en) * | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
| TW536403B (en) | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
-
1997
- 1997-06-23 BR BR9709939A patent/BR9709939A/pt unknown
- 1997-06-23 NZ NZ333099A patent/NZ333099A/en unknown
- 1997-06-23 US US09/202,660 patent/US6544961B1/en not_active Expired - Fee Related
- 1997-06-23 ES ES97928263T patent/ES2213217T3/es not_active Expired - Lifetime
- 1997-06-23 CA CA002258956A patent/CA2258956A1/en not_active Abandoned
- 1997-06-23 EA EA199801045A patent/EA001517B1/ru not_active IP Right Cessation
- 1997-06-23 KR KR1019980710646A patent/KR20000022226A/ko not_active Application Discontinuation
- 1997-06-23 AU AU32627/97A patent/AU727983B2/en not_active Ceased
- 1997-06-23 CO CO97034781A patent/CO4900074A1/es unknown
- 1997-06-23 TR TR1998/02704T patent/TR199802704T2/xx unknown
- 1997-06-23 PL PL97330747A patent/PL330747A1/xx unknown
- 1997-06-23 EP EP97928263A patent/EP0938321B1/en not_active Expired - Lifetime
- 1997-06-23 JP JP10502320A patent/JP2000515852A/ja not_active Ceased
- 1997-06-23 WO PCT/EP1997/003247 patent/WO1997049411A1/en active Search and Examination
- 1997-06-23 HU HU9903249A patent/HUP9903249A3/hu unknown
- 1997-06-23 AP APAP/P/1998/001419A patent/AP9801419A0/en unknown
- 1997-06-23 ID IDP972147A patent/ID19490A/id unknown
- 1997-06-23 AT AT97928263T patent/ATE257708T1/de not_active IP Right Cessation
- 1997-06-23 DE DE69727240T patent/DE69727240T2/de not_active Expired - Fee Related
- 1997-06-23 CN CN97197357A patent/CN1228026A/zh active Pending
- 1997-06-23 IL IL12735197A patent/IL127351A0/xx unknown
- 1997-06-23 CZ CZ984294A patent/CZ429498A3/cs unknown
- 1997-08-05 TW TW086111193A patent/TW469132B/zh active
-
1998
- 1998-11-30 IS IS4915A patent/IS4915A/is unknown
- 1998-12-16 YU YU58398A patent/YU58398A/sr unknown
- 1998-12-22 NO NO986034A patent/NO986034L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9903249A3 (en) | 2001-04-28 |
| ES2213217T3 (es) | 2004-08-16 |
| CA2258956A1 (en) | 1997-12-31 |
| US6544961B1 (en) | 2003-04-08 |
| ID19490A (id) | 1998-07-16 |
| DE69727240T2 (de) | 2004-11-25 |
| AU727983B2 (en) | 2001-01-04 |
| KR20000022226A (ko) | 2000-04-25 |
| CO4900074A1 (es) | 2000-03-27 |
| ATE257708T1 (de) | 2004-01-15 |
| EA001517B1 (ru) | 2001-04-23 |
| BR9709939A (pt) | 1999-08-10 |
| NO986034D0 (no) | 1998-12-22 |
| WO1997049411A1 (en) | 1997-12-31 |
| NZ333099A (en) | 2000-06-23 |
| AP9801419A0 (en) | 1998-12-31 |
| CZ429498A3 (cs) | 1999-06-16 |
| EP0938321A1 (en) | 1999-09-01 |
| NO986034L (no) | 1999-02-23 |
| IS4915A (is) | 1998-11-30 |
| AU3262797A (en) | 1998-01-14 |
| JP2000515852A (ja) | 2000-11-28 |
| TW469132B (en) | 2001-12-21 |
| EP0938321B1 (en) | 2004-01-14 |
| HUP9903249A2 (hu) | 2000-10-28 |
| IL127351A0 (en) | 1999-10-28 |
| TR199802704T2 (xx) | 1999-03-22 |
| PL330747A1 (en) | 1999-05-24 |
| CN1228026A (zh) | 1999-09-08 |
| EA199801045A1 (ru) | 1999-08-26 |
| DE69727240D1 (de) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU58398A (en) | Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv | |
| EA199700203A1 (ru) | Синергические комбинации зидовудина, 1592u89 и 3тс или ftc | |
| TNSN92070A1 (fr) | Les analogues du necleoside de 13-oxathiolane | |
| RU94013464A (ru) | Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции | |
| BRPI0406760A (pt) | Composições e métodos para terapia antiviral de combinação | |
| MEP32208A (en) | Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients | |
| BR0311154A (pt) | Composição para melhorar o melasma e composição para reduzir a opacidade da pele | |
| EA199900757A1 (ru) | Фармацевтические композиции | |
| YU58498A (en) | Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv | |
| BR9916919A (pt) | Compósito de sulfonamida e seu uso | |
| AR007616A1 (es) | Combinaciones antivirales | |
| AR023661A1 (es) | Combinaciones antivirales | |
| AU2003291457A1 (en) | Pharmaceutical antiviral compositions | |
| WO2000018383A3 (en) | Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester | |
| WO2001030329A3 (en) | Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction | |
| AR043332A1 (es) | Composiciones y metodos para terapia antiviral | |
| TH34798A (th) | การรวมสารต้านไวรัส | |
| AR040805A1 (es) | Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral | |
| WO2000018384A3 (en) | Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir |